N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis

Sponsor: Centre Hospitalier Universitaire de Saint Etienne • ClinicalTrials.gov ID: NCT05571514

Registry updated: 2026-10-02
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Post-menopausal osteoporosis and the resulting fractures are an important cause of disability and loss of independence. They also increase the risk of morbidity and mortality. Given potential side effects, hormone replacement therapy is no longer recommended for menopausal women with risk of becoming osteoporotic. The very significant decrease in the use of these treatments is suspected of contributing to a resurgence in the incidence of osteoporotic fractures, particularly in women before the age of 70. There is a need for prevention of osteoporosis.

Interventions

  • Mother-of-pearl (Dietary supplement)
    The mother-of-pearl, derived from the inner shell of marine molluscs, is composed of calcium carbonate and organic compounds, some of which peptides are active on the bone. The mineralization inducing activity of the molecules extracted from the mother-of-pearl has been shown in vitro. Mother-of-pearl extract also contains molecules that inhibit the resorption activity of osteoclasts. Mother-of-pearl compounds can thus slow bone remodelling as showed in an ovariectomy-induced osteoporosis model in rat, where mother-of-pearl supplementation showed a better effect on limitation of bone loss than calcium carbonate supplementation.
  • Calcium Carbonate (Dietary supplement)
    Calcium carbonate is a source of calcium.

Eligibility criteria

Inclusion Criteria: * Post-menopausal women (50-65y) with risk of becoming osteoporotic * T-score between -1 and -3 * Absence of fragility fractures history Exclusion Criteria: * absence of parathyroid glands (phospho-calcic regulation) * presence of kidney stones * patients who follow a treatment that could interfere with bone metabolism (corticotherapy, menopausal hormonal therapy, anti-oestrogen treatment, non-controlled hyperthyroiditis, hyper- and hypothyroiditis) * bone diseases (Paget'disease, osteomalacia) * chronic alcoholism

Conditions

Post Menopausal Osteoporosis

Locations

  • Hôpital Gabriel Montpied — Clermont-Ferrand, France
  • Clinique Universitaire de Rhumatologie — Grenoble, France
  • CH Emile Roux — Le Puy-en-Velay, France
  • Hôpital Edouard Herriot — Lyon, France
  • APHP - Hôpital Cochin — Paris, France
  • CH Roanne — Roanne, France
  • CHU Saint-Etienne — Saint-Etienne, France
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record